Innovating respiratory therapy for your patients
At a minimum, OXFO triples the time your oxygen cylinder maintains your target oxygen saturation(SpO2)
We invite you to discover OXFO in this video.
The content of this video is for illustrative purposes only.
Why the variability of FIO2
In a patient requiring supplemental oxygen, current systems deliver a constant oxygen flow, and the consistency of the air-oxygen mixture will vary depending on the patient’s activity level, which is directly correlated with airflow variability.
With OXFO equipment, the oxygen flow is delivered variably, maintaining the consistency of the air-oxygen mixture naturally, according to the patient's activity level.
CLINICAL STUDIES
Results: Oxygen Savings
Randomized, crossover study.
20 pacientes hospitalizados estables (Uno excluido)
- Age range 43-70
The prescribed supplemental O2 dose at the time of selection was 2-5 L/min
Results: Saturation
The average SpO2 for the OXFO Condition was 91.07% (SD=2.20%), compared to 91.35% (SD=1.62%) for the Standard Condition. The difference was not significant (p= 0.16).
The non-inferiority test of the OXFO Condition was significant (p<0.001).
Results: Volume
The OXFO Condition dispensed an average total of 3.6 L (SD=2.5 L) compared to 51.5 L (SD=27.0 L) during the Standard Condition (p<.001).
The OXFO Condition dispensed only 7.7% (SD=5.4%) of the total volume dispensed in the Standard Condition, representing a 92.3% conservation.
Results
The OXFO condition saved a significant amount of oxygen while achieving similar saturation levels.
Subjects tolerated the OXFO System as well as the standard treatment.
There were no adverse events, and all subjects completed the study.
Study Design
UDEA , Hospital Alma Mater de Antioquia, Colombia
- Single-visit, randomized, and crossover study design.
- 20 stable, hospitalized, and oxygen-dependent subjects (≥ 2 L/min), randomly assigned to receive either the OXFO Condition or the Standard Condition first.
- Subjects were administered oxygen for 20 minutes during each condition.
- Volume was measured every 5 minutes and SpO2 every minute.
- 1 subject was excluded from the analyses due to a protocol deviation.
Benefits for Patients
Natural Oxygen Dosage:
With OXFO, the patient controls the oxygen flow they need according to their inspiratory flow, aligned with their physical activity. This maximizes oxygen efficiency and duration, eliminates waste, and maintains proper oxygenation levels.
Potential Quality of Life Benefits:
Patients who have used the OXFO device have reported a significant improvement in their quality of life, enjoying greater freedom and ability to engage in physical activities. This not only positively impacts their mental and physical health but also enhances their social and economic well-being, benefiting both the patient and their family.
Portable Design
OXFO is compact, lightweight, weighing just over 1 pound, and easy to carry, providing the patient with greater autonomy and comfort.
Safety and Reliability:
OXFO is made from medical-grade materials, making it ideal for use in any respiratory therapy setting.
It is a Class IIA device, certified by INVIMA in Colombia, with additional medical registrations and scientific support through clinical studies.
Events and Conferences
In this calendar you will find upcoming events related to the world of breathing, in Colombia and the region.
Subscribe to our newsletter
Join our community of healthcare professionals! Sign up to receive updates on OXFO, respiratory therapy developments and continuing education opportunities
Find valuable information in the following organizations
Centers for Disease Control and Prevention
CDC is an American organization and a leader in public health, dedicated to protecting public health based on science and data. For over 70 years, it has worked to keep children healthy, strengthen communities and families, and fight diseases.
COPD Foundation
The mission of the COPD Foundation is to help millions of people live longer, healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.